Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. IBM
8. BLZE
9. NKE
10. MU

Go back to Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point

Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 51c; Lifts Revenue Outlook

November 9, 2022 4:26 PM EST

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $5.17, $0.51 better than the analyst estimate of $4.66. Revenue for the quarter came in at $940.65 million versus the consensus estimate of $939.97 million.

GUIDANCE:

Jazz Pharmaceuticals raises FY2022 revenue midpoint to $3.65 billion, versus the consensus... More